There is limited information available regarding the use of lurbinectedin during lactation. Lurbinectedin is a medication used in the treatment of certain types of cancer, particularly small cell lung cancer. However, the available sources do not provide specific details on the safety or potential effects of lurbinectedin on lactation or breast milk.

The drug patent information [1] and the FDA label [2] for lurbinectedin do not mention lactation or breastfeeding. These sources primarily focus on the drug's indications, dosage, and potential side effects. Therefore, it is unclear whether lurbinectedin can be safely used during lactation or if it is excreted in breast milk.

Additionally, the clinical trial database of the National Cancer Institute [3] does not provide any ongoing or completed studies specifically addressing the use of lurbinectedin during lactation.

Given the lack of available information, it is important to consult with a healthcare professional, such as an oncologist or a lactation specialist, who can provide personalized advice based on your specific situation. They can evaluate the potential risks and benefits of using lurbinectedin while breastfeeding and guide you in making an informed decision.

In conclusion, while there are no specific studies or information available on lurbinectedin and lactation, it is essential to consult with a healthcare professional to discuss the potential risks and benefits of using this medication during breastfeeding.

Sources:
[1] Drug Patent Watch. Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] U.S. Food and Drug Administration. Lurbinectedin FDA Label. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
[3] National Cancer Institute. Clinical Trials Database. Retrieved from https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2022-00578